CELESTONE SOLUSPAN Rx
Generic Name and Formulations:
Betamethasone sodium phosphate 3mg/mL, betamethasone acetate 3mg/mL; susp for IM, intra-articular or intralesional inj; contains benzalkonium chloride.
Merck & Co., Inc.
Indications for CELESTONE SOLUSPAN:
Steroid-responsive disorders when oral therapy not feasible.
See full labeling. Individualize. Titrate to lowest effective dose. Usual range: 0.25–9mg/day.
See full labeling. Individualize. Titrate to lowest effective dose. Initially 0.02–0.3mg/kg/day in 3 or 4 divided doses.
IM inj with idiopathic thrombocytopenic purpura.
Avoid IV administration. Not for treating traumatic brain injury or optic neuritis. Not for epidural use; serious neurologic events may occur. Concomitant systemic fungal infections, active ocular herpes simplex, cerebral malaria, live vaccines, previously injected joint: not recommended. Latent or active amebiasis. Strongyloides infection. Tuberculosis. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. CHF. Recent MI. Hypertension. Fluid retention. Renal insufficiency. Peptic ulcers. Diverticulitis. Intestinal anastomoses. Ulcerative colitis. Cirrhosis. Unstable or infected joints. Postmenopausal women (osteoporosis risk). Supplement with additional steroids in physiologic stress. Emotional instability. Psychotic tendencies. Myasthenia gravis. Avoid abrupt cessation. Monitor thyroid, weight, growth, fluid, electrolyte balance and intraocular pressure (w. therapy >6weeks). Pregnancy (Cat.C). Nursing mothers.
Potentiated by ketoconazole, macrolides, cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), cholestyramine. May potentiate cyclosporine (seizure risk). May antagonize anticoagulants (monitor), isoniazid. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin, other NSAIDs. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Concomitant neuromuscular blocking agents; increased risk of myopathy. Withdraw anticholinesterase agents at least 24hrs before initiating corticosteroid therapy. Aminoglutethimide may lead to loss of corticosteroid-induced adrenal suppression. May suppress reactions to skin tests.
HPA axis suppression, increased susceptibility to infection, glaucoma, cataracts, hypokalemia, hypocalcemia, hypernatremia, hypertension, thromboembolic disorders, psychic disorders, myopathy, osteoporosis, nausea, pancreatitis, peptic ulcer, dermal atrophy, increased sweating, impaired wound healing, increased intracranial pressure, carbohydrate and glucose intolerance, weight gain, inj site reactions, Kaposi's sarcoma, anaphylactoid reactions.
Multi-dose vial (5mL)—1
Psychiatry Advisor Articles
- ADHD, Comorbid Bipolar Disorder Share Similar Neurocognitive Profiles
- Anxiety Prevention Interventions: How Effective Are They?
- Antidepressant Use and Dementia Risk in the Elderly
- Sleep Apnea Implant Device Receives FDA Approval
- No Evidence of Personality Changes Prior to Developing Cognitive Impairment, Dementia
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Duration of Untreated Depression Predicts Depression Severity
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Cognitive Dysfunction a Sign of Prodromal Parkinson Disease
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Bipolar Depression Benefits From Midday Bright Light Therapy